Metabolomic Analysis of Systemic Sclerosis

  • End date
    Jul 11, 2024
  • participants needed
  • sponsor
    University Hospital, Strasbourg, France
Updated on 11 September 2021
early diagnosis
myocardial infarction
vascular disease
vascular disorder
systemic sclerosis
raynaud's phenomenon
raynaud's syndrome
raynaud phenomenon


Currently investigators do not have diagnostic and prognostic markers for SSc which almost always starts with a vascular disease (Raynaud's disease) isolated for several years.

The primary purpose is to highlight discriminating metabolic profiles depending on the characteristics of the disease, allowing early diagnosis of SSc at the onset of vascular lesions, by comparing the profiles of SSc beginners (<3 years) to established forms (> 3 years).

Secondary purposes:

  • Prognosis: to study the metabolomics profile of SSc when a visceral complication occurs
  • Diagnosis: to compare the metabolomics profile of SSc to undifferentiated connective tissue disease (UCDT), Raynaud's disease (RD), vascular disease (VD) and healthy controls
  • Exploratory: to compare the metabolomics profile of blood, urine and skin of SSc patients

Condition Raynaud's Disease, Vascular Diseases, Scleroderma, Systemic sclerosis, Peripheral vascular disease, Circulation Disorders, Undifferentiated Connective Tissue Disease, Healthy Control Subjects, vascular disorder, raynaud, raynaud's syndrome, raynaud's phenomenon, raynaud phenomenon, vascular disease, vasculopathy, vasc, progressive systemic sclerosis
Treatment - Skin biopsy - Urine sample - Blood sample
Clinical Study IdentifierNCT02298777
SponsorUniversity Hospital, Strasbourg, France
Last Modified on11 September 2021


Yes No Not Sure

Inclusion Criteria

Group 1 (scleroderma) : Patients with ACR / EULAR (2012) and / or criteria of Leroy and Medsger (2001)
Group 2 (UCDT) : Patients with criteria proposed by Mosca et al. (1998)
Group 3 (Raynaud) : Patients with primary and isolated Raynaud disease
Group 4 (vascular disease) : Patients with type 2 diabetes, occlusive vascular disease, history of myocardial infarction or ischemic stroke
Group 5 (healthy control) : healthy subjects (no sign of connective tissue disease, no Raynaud, no vascular disease)

Exclusion Criteria

Group 1 (scleroderma) : Patients not fulfilling ACR / EULAR (2012) and / or criteria of Leroy and Medsger (2001), or with another auto-immune disease
Group 2 (UCDT) : Patients not fulfilling criteria proposed by Mosca et al. (1998)
Group 3 (Raynaud) : Patients with no Raynaud disease
Group 4 (vascular disease) : Patients with no vascular disease
Group 5 (healthy control) : Patients with sign of connective tissue disease, Raynaud, or vascular disease)
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note